WisdomPath Technologies Files IPO Prospectus: Empowering Biopharmaceutical Innovation Through Medical Big Data Analytics
“It has become a consensus that the medical big data market boasts a scale worth tens of billions, and catalyzed by the pandemic, the era of medical big data has arrived.” Recently, Dr. Zhang Jianzhong, CEO of Huifang Technology, shared his insights with VCBeat on the current status, pain points, and future development of medical big data.
Dr. Zhang Jianzhong, CEO of Huifang Technology (Yi Shuju)
The development of medical big data in China can be traced back to the healthcare informatization initiatives launched during the 2009 healthcare reform, with electronic medical records serving as a key representative. Since 2015, the Chinese government has successively introduced industry standards and regulatory requirements for medical big data, sparking market momentum and promising substantial growth prospects. A number of early-established companies have successfully emerged from the competitive landscape, among which is Wuxi Huifang Technology Co., Ltd.
Since the national strategy for health and medical big data was released in 2016, the medical big data industry has progressed through early stages including data generation, collection, storage, and processing. The industrial value of data analysis and application is gradually becoming more prominent. “The vast amount of data aggregated within hospitals and various regional big data centers remains largely dormant; data monetization is the most pressing challenge facing the medical big data industry today.” The core objective of Huifang Technology is to unlock the value embedded in medical data for its clients.
Huifang Technology(Medical Data)Founded in Wuxi in 2011, Huifang Technology, under the leadership of its founder, Dr. Zhang Jianzhong, cultivated a corporate culture characterized by an relentless pursuit of technological excellence, meticulous product refinement, and an insatiable drive for innovation. Although Dr. Zhang only became aware of Inovalon, the U.S.-based healthcare big data analytics company that went public in 2015 and served as a benchmark competitor, after its IPO, Huifang’s corporate ethos bore striking similarities to that of Inovalon.
Much like Keith Dunleavy, the founder of Inovalon, Dr. Zhang Jianzhong is a top-tier interdisciplinary talent with an M.D. and clinical background. Since coming to the United States in 2000 for study and work, Dr. Zhang has long been engaged in professional and managerial roles in medical research and pharmaceutical R&D. Under his leadership, Wuxi Huifang Technology Co., Ltd. has pursued a pure technology-driven path, similar to that of Inovalon.
Huifang Technology’s technical team is primarily composed of interdisciplinary professionals specializing in software and information technology R&D, data management, biostatistics, and academic research. Its core technical backbone consists of high-caliber talents with extensive backgrounds in the pharmaceutical and IT industries, as well as outstanding professional expertise. The company has established branch offices and teams in Fuzhou, Xiamen, Jinan, and other locations. Furthermore, Huifang Technology plans to collaborate with academic institutions on talent development programs to ensure a sustainable pipeline of high-quality professionals for the future.
Leveraging its profound understanding of the medical big data industry, Wuxi Huifang Technology Co., Ltd. has been dedicated to this sector since 2011. By closely aligning with policy directions and market trends, the company is committed to the deep integration of information technology, medical science, and data technology, thereby promoting the practical application of big data technologies in healthcare and biomedical innovation.
Currently, Wuxi Huifang Technology Co., Ltd. focuses its business on serving clinical research and pharmaceutical R&D. In the field of clinical research, the company provides one-stop clinical research solutions to medical institutions at all levels, national and provincial/municipal clinical medicine research centers, and various research projects and funded programs, helping clients produce a greater volume of higher-quality academic outcomes more efficiently. In pharmaceutical R&D, Huifang Technology offers technical support—including software systems, data management, statistical analysis, and academic promotion—to clients such as pharmaceutical companies and CROs, thereby accelerating the pace of biomedical innovation.
The implementation of these businesses is supported by the "Yi Shu Ju" big data technology system independently developed by Huifang Technology.The “Yi Shuju” system features core functionalities in database construction, data governance, and data analysis and mining. Honed through hundreds of projects, the product has earned significant customer recognition for its professionalism and ease of use, with over 2,000 hospital departments across China having adopted it. Notably, in 2020, the system was certified by Jiangsu Province as a first-version software product in key fields, making it the only officially recognized product of its kind in the medical big data sector.
The prerequisite for the application of medical big data is data availability. Drawing on his extensive expertise in medical research and pharmaceutical R&D, Dr. Zhang Jianzhong, in light of the characteristics of medical data within hospitals,It is proposed that the connotation of medical big data governance should encompass three levels: data standardization governance, in-depth governance, and data management. Standardization governance addresses the issues of “dirty, disorganized, and poor-quality” medical data; in-depth governance involves the “deep and refined processing” of medical data based on application objectives; and data management serves as a prerequisite for statistical data analysis.
Centering on the core issue of robust data governance for big data analytics and mining in healthcare, Wuxi Huifang Technology Co., Ltd. continues to innovate in system R&D, parsing of unstructured medical data, flexible extraction of medical data, and full-process visualized governance of medical data.Developed a wide range of innovative technologies, including invention patents unique to the industry, addressing key pain points and challenges in the data governance process and making it possible to unlock the value of medical data.。
Dr. Zhang Jianzhong analyzed the technical roadmap of Huifang Technology using real-world hospital cases. Currently, there is a growing demand among hospitals to leverage existing internal medical data resources to produce high-quality academic and research outputs. However, even in Grade A tertiary hospitals, only a small fraction of physicians possess scientific research thinking and practical research experience. Furthermore, while data aggregation within hospitals is relatively easy, the data quality falls far short of applicable standards. Even if hospitals have deployed and implemented clinical research big data system platforms,Hospitals lack the independent capability to leverage such systems for data governance and scientific research implementation. There is an urgent need for third-party professional teams with composite competencies in system development, database construction, data governance, and academic research to assist hospitals in generating high-quality scholarly outcomes.
Leveraging its proprietary technology infrastructure, Wuxi Huifang Technology Co., Ltd. has implemented hundreds of clinical research and clinical trial projects, assisted investigators in designing and conducting numerous real-world study projects, and generated a substantial body of high-quality academic outputs. Its collaborative research platforms, anchored by specialty-specific and disease-specific databases, have become industry benchmarks.
In 2013, Huifang Technology completed its angel round of financing. Within two years after this initial funding, the company achieved self-sustainability, and within another three years, it turned profitable. Although its business scale was not large, it successfully met its goal of healthy growth. Currently, Huifang Technology has entered a phase of rapid expansion and is launching a new round of financing to integrate resources for large-scale market expansion and business implementation, enhance its market influence, and further strengthen R&D efforts, thereby solidifying its business processes and technological infrastructure.